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Molecular Imaging of the Remodeling Heart:
The Next Step Forward*
Barry Greenberg, MD, FACC
San Diego, CaliforniaCardiac remodeling is the term used to describe
changes in cardiac structure that occur following
injury to the heart and/or in response to long-
standing increases in loading conditions. Regardless
of the nature of the initial insult, the remodeling
process tends to be more or less uniform in nature.
Relatively well-described changes in gene expres-
sion produce prototypic phenotypic changes in
cardiac myocytes and fibroblasts that result in pro-
gressive deterioration in cardiac function and the
development of heart failure.
Imaging of the remodeling heart has enabled us
to define the timing of the process, magnitude of
increase in muscle mass and chamber volumes that
occur in various settings, presence of conforma-
tional changes in the heart, and, to a limited extent,
the tissue that is involved (e.g., amount of fibrosis).
See page 354
Currently available methods that focus on structural
and geometric changes, however, provide little in-
sight into the molecular mechanisms involved and
as such they describe relatively late downstream
events in the remodeling process. Theoretically,
information depicting changes at the molecular
level in cardiac cells should help identify individuals
at risk for remodeling as well as new targets for
therapy. Moreover, if such imaging could be per-
formed noninvasively with little risk to the patient,
sequential information obtained over time could
provide novel mechanistic insights and assess the
adequacy of therapeutic interventions.
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.From the University of California, San Diego. H. William Strauss, MD,
served as Guest Editor for this article.The renin-angiotensin system (RAS) plays a
major role in cardiac remodeling. Angiotensin
(Ang) II, the key effector molecule of the RAS,
interacts with specific cell surface receptors to ini-
tiate changes that are critical to the progression of
the remodeling process. Although several Ang pep-
tide receptors have been identified, the most im-
portant of these is the type 1 or AT1 receptor.
Interestingly, this receptor is considerably more
abundant on cardiac fibroblasts than on myocytes
(1). In the post-myocardial infarction (MI) remod-
eling heart, the density of the AT1-receptor popu-
lation on cardiac fibroblasts is increased, a process
that appears to be driven by release of proinflam-
matory cytokines (2,3). The AT1 receptor on fibro-
blasts mediates Ang II-stimulated production of
extracellular matrix proteins (ECMs) and also tissue
inhibitors of metalloproteinases that regulate ECM
breakdown. Increases in receptor density have been
shown to significantly enhance these Ang II effects
(4). Evidence that Ang II-stimulated cardiac myo-
cyte hypertrophy is dependent on the release of
secondary growth factors from fibroblasts further
emphasizes the central role of the AT1 receptor on
cardiac fibroblasts in the remodeling process (5). In
the remodeling heart, increased AT1 receptor den-
sity occurs at a time when local production of Ang
II is increased, providing conditions for a “perfect
storm” as far as remodeling is concerned.
In the present study, evidence of AT1 receptor
up-regulation in the infarct and border zones was seen
during the period when post-MI remodeling is most
intense. Rapid replacement of devitalized myocardium
with firm scar tissue prevents cardiac rupture and also
helps reduce wall stress by limiting chamber expan-
sion. In that regard, the initial RAS activation in the
infarct zone is helpful because the transformed myo-
fibroblasts that migrate to the region play a major role
in breaking down existing scaffolding and generating
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364he ECM proteins that form the replacement scar.
hese same processes, however, are activated in re-
ote noninfarcted regions of myocardium where they
ead to the deposition of perivascular and interstitial
brosis. The resultant disordering of the ECM and
ncrease in fibrous tissue adversely effects both systolic
nd diastolic functions of the heart. Efforts to coun-
eract RAS activation with either angiotensin-
onverting enzyme inhibitors or angiotensin receptor
lockers inhibit remodeling and favorably alter the
atural history of heart failure in both experimental
nimal models and human patients (6–9). As a result,
hese agents are strongly recommended in heart failure
uidelines with increasing emphasis on early recogni-
ion and treatment of patients at risk (10).
In this issue of JACC: Cardiovascular Imaging,
erjans et al. (11) provide exciting information
bout imaging of Ang receptors in the post-MI
emodeling heart. To accomplish this, they used
complimentary approaches. In the first, a
uorescein-labeled Ang peptide analogue was ad-
inistered intravenously to mice beginning at 30
in and then at various times up to 12 weeks after
eft anterior descending coronary artery ligation.
eal-time in vivo optical imaging of open-chested
ice was performed using a fluorescence stereomi-
roscope attached to a camera. Their results show
hat uptake of tracer was observed in the infarct
egion as early as 1 day post-MI and that it had
ncreased substantially at 1 week. By 6 weeks,
uorescence (seen predominantly in the border
one at this time) was decreased, a process that
ontinued until the last measurement 12 weeks
ost-MI. This time course, which paralleled the
evelopment of echocardiographic LV dilation, is
onsistent with previous reports of post-MI remod-
ling in this model (12). Subsequent examination of
ardiac tissue indicated that the source of fluores-
ence was the population of collagen-producing
yofibroblasts located in the infarct and border
ones. Previous reports have documented an influx
f these cells and up-regulation in their AT1-
eceptor density post-MI that closely parallels the
ndings in the present study (3).
The investigators also performed micro–single-
hoton emission computed tomography (SPECT)
nd micro-computed tomography imaging using
adiolabeled losartan at 3 weeks post-MI. Specific-
ty of this compound for the AT1 receptor con-
rmed that the signal originated from tracer bind-
ng at this receptor rather than at the AT2 or other
ng receptors. Uptake was seen in the anterolateral
ardiac image by SPECT, and ex vivo imaging nonfirmed that this originated from the infarct and
order zones. Quantitative assessment indicated
hat uptake was significantly higher in post-MI
han in noninfarcted control hearts.
The ability to visualize changes in the expression
f the AT1 receptor in the remodeling heart in vivo
epresents an important step in our efforts to pre-
ent and/or inhibit remodeling. In a sense, it brings
s “closer” to the action and as such holds the
romise of allowing early identification of patients
t risk and also of determining the adequacy of
herapies designed to inactivate the RAS. In this
articular case, one could imagine using AT1-
eceptor imaging to define patients who are at risk
or remodeling in a variety of settings including
ost-MI. If such patients were then treated with an
ngiotensin-receptor blocker, imaging could be
sed to determine how effective the agent and dose
as in blocking tracer uptake within the heart.
ontinued high levels of signal despite therapy
ight indicate that additional drugs or approaches
re required. The demonstration that molecular
athways within the remodeling heart are ap-
roachable by in vivo imaging also indicates that it
s possible to assess trafficking within critical sig-
aling pathways stimulated by the RAS and other
ystems that are believed to play a role in cardiac
emodeling. Information from future studies could
hus provide powerful insights into the activation of
hese systems as well as the effects of various
reatments.
It is important to recognize that as exciting as
hese results are, much work still needs to be done.
maging in these experiments was performed in an
pen-chest model and translation of these results to
closed-chest human patient who may have post-
perative fibrotic tissue as well as considerable
mounts of muscle, adipose tissue, or air (in the case
f the emphysematous patient) between the heart
nd the camera will obviously take considerable
mounts of work. In addition, imaging of the AT1
eceptor in the infarct and peri-infarct zone repre-
ents a relatively easy target because the increase is
oncentrated into relatively circumscribed zones.
maging of more diffuse signals that originate in
oninfarcted myocardium where AT1-receptor ef-
ects are more clearly deleterious is likely to be
hallenging. If this approach is going to be impor-
ant in determining adequacy of therapy, an impor-
ant early step would be to assess the effect of
reatment with agents such as angiotensin-receptor
lockers on the intensity of the signal that origi-
ates from the AT1 receptor.
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365Nonetheless, the results reported here are im-
ressive and the promise for future advances that
hey imply is considerable. The investigators de-
erve much credit for demonstrating that a physio-
ogically relevant molecule whose expression is al-
ered in remodeling hearts could be imaged in a
iving animal. Although it may be only a step, it
learly is an important one. Further work in thismediated cardiac fibroblast responses Effect of captoprilivo imaging of molecular events in the remodeling
eart will become a reality in patients in the not so
istant future.
eprint requests and correspondence: Dr. Barry Green-
erg, Professor of Medicine, Director, Advanced Heart
ailure Treatment Program, University of California, San
iego, 200 West Arbor Street, San Diego, Californiarea will hopefully move along quickly so that in 92103– 8411. E-mail: bgreenberg@ucsd.edu.1
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